Search This Blog

Monday, September 28, 2020

FDA OKs Cipla's generic version of Biogen's Tecfidera

The FDA approves Mumbai, India-based Cipla Limited's generic version of Biogen's (NASDAQ:BIIB) top-selling multiple sclerosis med Tecfidera (dimethyl fumarate).

Last month, Mylan launched its version.

Tecfidera accounted for 32% of Biogen's Q2 sales.

https://seekingalpha.com/news/3617621-fda-oks-ciplas-generic-version-of-biogens-tecfidera

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.